The Annual Meeting of the International Conference on Genomics

Conference Opening

To commemorate the 25^th anniversary of the Human Genome Project (HGP) Chinese Volume Preparatory Meeting and the 20^th anniversary of the completion of the Human Genome Project, the 18^th Annual Meeting of the International Conference on Genomics (ICG-18) was held in Singapore on April 22 and 23, 2023. Yang Huanming, academician of the Chinese Academy of Sciences, Mohamed HASSAN, president of the World Academy of Sciences, Fred DUBEE, co-chairman of the ICG International Advisory Group, Sir Royal of the United Kingdom, Walter BODMER, academician of the Royal Academy of Sciences of the United Kingdom, Antoine DANCHIN, academician of the French Academy of Sciences, senior scientific adviser to the Director General of WHO and Peter SINGER, member of TWAS, and other top scientists, medical experts and industry leaders gathered together to discuss the latest progress and future development trends in the field of genomics, aiming to promote in-depth exchanges and cooperation in the field of global genomics research.

Roundtable Forum

Dr. Tammy Tan, chairman of HymonBio Co., Ltd., was invited to participate in the roundtable forum “Biological Century – How Innovative Technology Changes the Global Development Imbalance,” and covered four major platforms of cancer screening, infectious diseases, immunofluorescence, and freeze-dry technology, combined with HymonBio’s patented ECS Magnetic Bead Extraction Technology, Molecular Lock Amplification Technology, and OT Buffer System, demonstrating the strength of nucleic acid testing in China.

HYMON

Never Stop Moving Forward

Based on solving clinical diagnosis and treatment problems, HymonBio is committed to cutting-edge technological innovation in biology. We adhere to creating high-quality and high-standard products at the international level, focusing on gene expression regulation and cancer pathogenesis research, developing advanced diagnostic reagents for early cancer screening and infectious diseases, and provide scientific and technological support for the precision medicine industry and research, development, and production of POCT-related products. In the future, we will continue to rely on innovative technology, open up the market with revolutionary products, serve customers on a global scale with a full range of technical services, and improve clinical benefits of more patients.